Drugs.com - Pharma Industry News

Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC

TUESDAY, Feb. 4, 2025 -- For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen [mFOLFOX6]) is...

Feb 9, 2025 - 21:45
 0
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
TUESDAY, Feb. 4, 2025 -- For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen [mFOLFOX6]) is...
Read More

Tags:

Previous Article

Mental Health Conditions Common in Pediatric Stroke Survivors

Next Article

Recording of Nystagmus During Vertigo in Meniere Disease May Offer Therapeutic Aid

Related Posts

Physical Activity Linked to Attenuation of Colon Cancer Survival Disparity

Physical Activity Linked to Attenuation of Colon Cancer...

Feb 24, 2025  0

Stressors Affect Systemic Inflammation, Tumor Aggressiveness in Breast Cancer

Stressors Affect Systemic Inflammation, Tumor Aggressiv...

Feb 27, 2025  0

Recent Decade Saw Rise in Number of Adults With Severe Obesity

Recent Decade Saw Rise in Number of Adults With Severe ...

Feb 20, 2025  0